ライフサイエンスコーパス: BCG vaccination

1 IP may provide a novel adjuvant strategy for BCG vaccination.

2 t were strongest after BCG/rAd85A and rAd85A/BCG vaccination.

3 following M. tuberculosis infection or after BCG vaccination.

4 ection status, bacterial drug resistance, or BCG vaccination.

5 t in acquired immunity conferred by M. bovis BCG vaccination.

6 gens were significantly enhanced by M. bovis BCG vaccination.

7 ewer tubercles than did intradermal M. bovis BCG vaccination.

8 immune responses to mycobacteria induced by BCG vaccination.

9 ater than in vaccinees administered a single BCG vaccination.

10 ith degree of exposure to the index case and BCG vaccination.

11 , which was comparable with that afforded by BCG vaccination.

12 the levels were significantly enhanced after BCG vaccination.

13 phages infected with live mycobacteria after BCG vaccination.

14 ation of IFN-gamma mRNA expression following BCG vaccination.

15 xposed to various stimuli was enhanced after BCG vaccination.

16 uishes between M. tuberculosis infection and BCG vaccination.

17 s adjuvants to increase the effectiveness of BCG vaccination.

18 sting of 15 mm or greater 1 to 3 years after BCG vaccination.

19 investigate human T cell subsets induced by BCG vaccination.

20 azimine selectively expands Tcm cells during BCG vaccination.

21 ad presented with BCG osteitis after newborn BCG vaccination.

22 ge 6 to 11 years for children given neonatal BCG vaccination.

23 the human host response induced by neonatal BCG vaccination.

24 rs2275913 was associated with osteitis after BCG vaccination.

25 able to that provided by Mycobacterium bovis BCG vaccination.

26 ) vaccination after infancy or with repeated BCG vaccinations.

27 (TB) infection and bacillus Calmette Guerin (BCG) vaccination.

28 eous or intradermal bacille Calmette-Guerin (BCG) vaccination.

29 were 10 mm or greater than did percutaneous BCG vaccination (12 of 46 participants compared with 1 o

30 mune responses following Mycobacterium bovis BCG vaccination, 15-mer synthetic peptides were synthesi

31 (+) T cells, in immunity induced by M. bovis BCG vaccination, 4-week-old specific-pathogen-free pigs

32 Three months after BCG vaccination, 51 (100%) of 51 UK infants had an IFN-g

33 volunteers who had received two intradermal BCG vaccinations 6 months apart.

34 s with a history of Bacille Calmette-Guerin (BCG) vaccination after infancy or with repeated BCG vacc

35 ext of experimental bacille Calmette-Guerin (BCG) vaccination, Ag-specific T cell responses to mycoba

36 ssess the heterologous protective effects of BCG vaccination against respiratory infection (RI) and s

37 s: this showed that the protective effect of BCG vaccination against the development of asthma identi

38 ariable efficacy of Bacille Calmette Guerin (BCG) vaccination against tuberculosis has prompted effor

39 ogy in four/eight parameters assessed, while BCG vaccination alone did so in only one parameter studi

40 Depletion of NK1.1(+) cells at the time of BCG vaccination also increased the bacillary burden and

41 s with active tuberculosis (P<.05), and oral BCG vaccination also induced significant increases in LA

42 ght be affected by various factors including BCG vaccination and age, our results suggest that the pr

43 confounders, we found no association between BCG vaccination and asthma.

44 fected controls, while in kinetic studies of BCG vaccination and INH treatment we compared pre-experi

45 n both cattle models of protective immunity (BCG vaccination and INH treatment) was transient over ti

46 Widespread BCG vaccination and multidrug therapy have dramatically

47 patients with active tuberculosis even after BCG vaccination and suggest that combinatorial use of an

48 y ages are functionally enhanced by M. bovis BCG vaccination and suggests an important role for this

49 esponses induced by bacille Calmette-Guerin (BCG) vaccination and active tuberculosis infection were

50 ssociation between bacillus Calmette-Guerin (BCG) vaccination and childhood asthma in a birth cohort

51 g IFN-gamma during bacillus Calmette-Guerin (BCG) vaccination and subsequent M. tuberculosis challeng

52 ce/ethnicity, poverty, education, history of BCG vaccination, and history of household exposure to tu

53 We accounted for the effects of age, BCG vaccination, and HIV infection.

54 lation differences in immune responses after BCG vaccination are observed among infants, as well as a

55 ound to mount Th1-like responses to M. bovis BCG vaccination as determined by immunoproliferation and

56 tion in school-aged children who had had one BCG vaccination as infants.

57 in skin test (TST) negative and eligible for BCG vaccination as part of the last round of Norway's ma

58 Mycobacterium bovis bacille Calmette-Guerin (BCG) vaccination as a surrogate for M. tuberculosis infe

59 ed infants were randomly assigned to receive BCG vaccination at birth (the early vaccination arm) or

60 BCG vaccination at birth may decrease hospitalization du

61 sitization biases T cell immunity induced by BCG vaccination away from type 1 IFN-gamma responses ass

62 BCG vaccination, blood samples drawn for immunologic stu

63 cells at an early time point after M. bovis BCG vaccination, but CD4(+) T cells were found to be mor

64 Studies have suggested that BCG vaccination can have nonspecific effects, reducing g

65 reventing tuberculosis is uncertain and that BCG vaccination can interfere with the detection and tre

66 ts for age at vaccination, tribe, subsequent BCG vaccination, chronic medical illness, isoniazid use,

67 mycobacteria and/or bacille Calmette-Guerin (BCG) vaccination compromise the estimates derived from p

68 The protection observed following BCG vaccination concurrent with anti-IL-10R mAb treatmen

69 BCG vaccination conferred the advantage of recruiting gr

70 At US2-3 dollars per dose, BCG vaccination costs US206 dollars (150-272) per year o

71 We hypothesized that BCG vaccination could also enhance immune responses to i

72 however, the addition of IL-12 or CpG ODN to BCG vaccination did not alter granuloma formation or res

73 atic review and meta-analysis suggested that BCG vaccination did not protect against allergic sensiti

74 The effect of neonatal BCG vaccination differed significantly between children

75 ability to detect LTBI, was less affected by BCG vaccination, discriminated responses due to nontuber

76 w that treatment with these two drugs during BCG vaccination dramatically improves vaccine efficacy.

77 ta activity augments the initial response to BCG vaccination, early bacterial clearance may adversely

78 ng novel vaccines, since Mycobacterium bovis BCG vaccination effectively prolongs survival after low-

79 BCG vaccination enhanced the number of IFN-gamma-produci

80 icate that inclusion of CT in the intranasal BCG vaccination enhances COX-2-mediated PGE(2) release b

81 ow that inhibition of IL-10 signaling during BCG vaccination enhances host-generated Ag-specific IFN-

82 ermore, mice that received clofazimine after BCG vaccination exhibited significantly enhanced resista

83 s, such as IPT and bacillus Calmette-Guerin (BCG) vaccination for preventing TB disease among exposed

84 for use as diagnostic markers to distinguish BCG vaccination from latent tuberculosis.

85 pment of new diagnostic tests to distinguish BCG vaccination from tuberculosis infection.

86 Although widely used, Mycobacterium bovis BCG vaccination given at birth does not protect against

87 We estimated that the 100.5 million BCG vaccinations given to infants in 2002 will have prev

88 These initial studies indicate that BCG vaccination has a positive effect on IL-1 beta and R

89 Previous studies have found that BCG vaccination has nonspecific beneficial effects on ch

90 Why BCG vaccination has not reduced disease prevalence, espe

91 Bacille Calmette-Guerin (BCG) vaccination has been suggested to have nonspecific

92 y against mycobacteria are upregulated after BCG vaccination; however, a significantly weaker respons

93 ing system, we were able to demonstrate that BCG vaccination imparted significant protection by reduc

94 BCG (BCG lux), to study immune responses to BCG vaccination in 50 neonates in a setting in Cape Town

95 Organization recommends Mycobacterium bovis BCG vaccination in areas of high tuberculosis prevalence

96 The immunogenicity of BCG vaccination in HIV-exposed, uninfected infants is no

97 systemic mycobacterial infection in mice and BCG vaccination in humans.

98 BCG-reactive memory NK cells were induced by BCG vaccination in infants, whereas in vitro IFN-gamma e

99 ults differ from those of studies of delayed BCG vaccination in South Africa and the Gambia, suggesti

100 cellular and molecular responses induced by BCG vaccination in the guinea pig model of pulmonary tub

101 ed by histopathology, and resembled M. bovis BCG vaccination in this respect.

102 Here we show that bacille Calmette-Guerin (BCG) vaccination in healthy volunteers led not only to a

103 BCG vaccination increased fluid volume and cellular accu

104 Depletion of NK1.1(+) cells at the time of BCG vaccination increased the number of immunosuppressiv

105 Intradermal BCG vaccination induced a larger number of persistent re

106 ig IFN-gamma (gpIFN-gamma) and reported that BCG vaccination induced a significant increase in the IF

107 with nonsensitized controls, indicating that BCG vaccination induced gamma delta T cell activation as

108 BCG vaccination induced significantly higher gamma inter

109 In experimental studies, BCG vaccination induced T- and B-lymphocyte-independent

110 Systemic BCG vaccination induced up to 600-fold increases in expr

111 Bacille Calmette-Guerin (BCG) vaccination induces a marked increase in the interf

112 expression levels of 138 immune genes after BCG vaccination/infection of rhesus macaques.

113 t of vaccine-elicited T cell responses after BCG vaccination/infection.

114 ek and was sustained at > or = 6 weeks after BCG vaccination/infection.

115 o optimally study immune gene networks after BCG vaccination/infection.

116 ogether with the unexpected observation that BCG vaccination influenced M. avium subsp. paratuberculo

117 BCG vaccination is a highly cost-effective intervention

118 e generation of host Th1 responses following BCG vaccination is accepted as the major mechanism of pr

119 BCG vaccination is routine in Brazil but BCG revaccinati

120 ycobacterium bovis bacillus Calmette-Guerin (BCG) vaccination is efficacious for newborns or adults w

121 Bacille Calmette-Guerin (BCG) vaccination, known to induce partial protection aga

122 in vaccinated and nonvaccinated populations, BCG vaccination led to TB case declines of 15.4% and 21.

123 toms of sepsis, but 18 of 33 infants without BCG vaccination lesions did.

124 idly from antigen-presenting cells following BCG vaccination, maintenance of OX40-expressing vaccine-

125 Our data show that BCG vaccination may be effective in protecting children

126 Bacille Calmette-Guerin (BCG) vaccination may induce persistent and booster purif

127 ave suggested that Bacillus Calmette-Guerin (BCG) vaccination may reduce the risk of allergic disease

128 However, unlike BCG vaccination, MPB83 DNA vaccination did not protect c

129 roinflammatory leukocyte responses following BCG vaccination, nonspecific effects of influenza vaccin

130 as associated with bacillus Calmette-Guerin (BCG) vaccination (odds ratio: 25.1 [95% confidence inter

131 the effectiveness of treatment programs, and BCG vaccination of HIV-negative homeless individuals hav

132 e longitudinal CD4 T-cell response following BCG vaccination of human newborns.

133 o have beneficial nonspecific effects; early BCG vaccination of low-birth-weight (LBW) newborns reduc

134 earer evidence that any protective effect of BCG vaccination on childhood asthma is likely to be tran

135 We studied the effects of BCG vaccination on gene expression in tuberculosis granu

136 The effect of Mycobacterium bovis BCG vaccination on interleukin-1 beta (IL-1 beta) or reg

137 was to determine the effect of this delay in BCG vaccination on the induced immune response.

138 t to assess whether the protective effect of BCG vaccination on wheeze observed in the MANCAS cohort

139 adily trafficked to the airway or lung after BCG vaccination or M. tuberculosis infection, and some o

140 ically significant waning of the efficacy of BCG vaccination over time, greater among men than women.

141 eas ELISPOT results were not associated with BCG vaccination (p=0.44).

142 BCG vaccination prevents disseminated tuberculosis in ch

143 BCG vaccination prior to influenza vaccination results i

144 A BCG vaccination program that reached 10% of eligible chi

145 tive therapy and treatment, coupled with the BCG vaccination program, would lead to a 47% decline in

146 's mandatory mass tuberculosis screening and BCG vaccination programme between 1962 and 1975.

147 rograms with targeted preventive therapy and BCG vaccination programs.

148 ous inhibition of Th2 cells and Tregs during BCG vaccination promotes vaccine efficacy.

149 Taken together, these data demonstrate that BCG vaccination protects against infection with diverse

150 ges of gammadelta T cells caused by M. bovis BCG vaccination rather than being due solely to help fro

151 Previous BCG vaccination reduces the predictive value of serial P

152 Nonspecific effects of BCG vaccination related to enhanced function of myeloid

153 e, Ab blockade of IL-10R specifically during BCG vaccination resulted in additional protection agains

154 These results indicate that the BCG vaccination route can affect both in vivo and in vit

155 Recent intradermal BCG vaccination significantly enhanced the inhibitory ac

156 , rMtb72F delivered by coadministration with BCG vaccination significantly improved the survival of t

157 BCG vaccination significantly reduced growth of BCG lux

158 st, ELISPOT results were not correlated with BCG vaccination status (p=0.7), whereas TST results were

159 BCG vaccination status was determined from health record

160 n Immunity and Health (1974-1994), including BCG vaccination status, perinatal and sociodemographic c

161 tal zone of residence, country of birth, and BCG vaccination status, while occupations were placed in

162 yses examined age, bacillus Calmette-Guerin (BCG) vaccination status, and sex as predictor variables

163 mammalian host, in particular with regard to BCG vaccination strategies.

164 support further evaluation of this modified BCG vaccination strategy for HIV-exposed infants.

165 and the type of immune responses elicited by BCG vaccination to enable comparisons with potential new

166 pport a role for immune adjuvants given with BCG vaccination to enhance its biologic efficacy.

167 Many countries offer a second BCG vaccination to prevent tuberculosis, although there

168 ycobacterium bovis bacillus Calmette-Guerin (BCG) vaccination to protect against mycobacterial infect

169 We aimed to determine whether neonatal BCG vaccination, vitamin A supplementation and other vac

170 FN-gamma production evaluated 10-14 mo after BCG vaccination was 26-fold higher for infants who were

171 ry immunity conferred by Mycobacterium bovis BCG vaccination was affected in mice with chronic enteri

172 Prior BCG vaccination was associated with a negative IFN-gamma

173 In infants <6 months old, recent BCG vaccination was associated with a non-M. tuberculosi

174 trend was observed with guinea pigs in which BCG vaccination was boosted by DNA vaccination, although

175 ve tuberculin skin test (OR, 2.21; P = .03); BCG vaccination was particularly protective, especially

176 e majority of gamma delta T cells induced by BCG vaccination were gamma 9+ delta 2+ T cells reactive

177 Effects of primary and booster intradermal BCG vaccinations were assessed in 3 distinct assays of m

178 nd than elsewhere at the time when universal BCG vaccinations were given to Finnish newborns.

179 imary or secondary bacillus Calmette-Guerin (BCG) vaccination were assessed for Ab responses to AM vi

180 sis that the coadministration or boosting of BCG vaccination with Mtb72F may limit the lung consolida

181 To determine whether Mycobacterium bovis BCG vaccination would alter gamma interferon (IFN-gamma)

182 hesized that Mtb PPD-induced IFN-gamma after BCG vaccination would be similar in infants from these 2